Clinical Trials
40 trialsTroFuse-036
Merck Sharp & Dohme LLC
DOVE
Yonsei University
ANGELICA
Centre Leon Berard
BEATcc
Grupo Español de Investigación en Cáncer de Ovario
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Seagen Inc.
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
KEYNOTE-826
Merck Sharp & Dohme LLC
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Akeso
KEYVIBE-005
Merck Sharp & Dohme LLC
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Akeso
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Bio-Thera Solutions
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
University of Miami
Study of ZG005 in Combination With Paclitaxel+Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
EMD Serono
Clovis-001
University of Oklahoma
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
National Cancer Institute (NCI)
A Phase I Clinical Trial of Bevacizumab Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Zhejiang Cancer Hospital
A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer
Sichuan Cancer Hospital and Research Institute
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Sun Yat-sen University
Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer
Peking Union Medical College Hospital
FERMATA
Biocad
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
National Cancer Institute (NCI)
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
National Cancer Institute (NCI)
Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer
Hoffmann-La Roche
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)
Biocad
Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
University of Alabama at Birmingham
Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
National Cancer Institute (NCI)
Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
Leo W. Jenkins Cancer Center
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Dana-Farber Cancer Institute
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
Washington University School of Medicine
Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
M.D. Anderson Cancer Center